FDA
-
-
-
-
-
-
-
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
-
-
-
-
-
-
-
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
-
-
-
-
-
-
-
Foundayo and Zepbound now covered for millions of Americans
-
-
-
-
-
-
-
Lilly reports weight maintenance with Foundayo and reduced-dose Zepbound
-
-
-
-
-
-
-
Novo Nordisk reports Q1 earnings on Wednesday: Analysts flag key focus topics
-
-
-
-
-
-
-
Eli Lilly & Co. (LLY) shares trade lower on weak Foundayo launch
-
-
-
-
-
-
-
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of card
-
322,995 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

